

VACCINE INVESTMENT STRATEGY 2024

BOARD MEETING


Marta Tufet Bayona

26-27 June 2023, Geneva, Switzerland




Vaccine Investment Strategy informs Gavi 6.0 (2026–2030)

Evidence-based approach to identify immunisation investments for future strategic cycle(s), while sending valuable advance signals to vaccine developers and suppliers



← In response to public health threat or a research and development (R&D) milestone for a priority pathogen, diseases of epidemic/pandemic potential can be evaluated in real time, outside five-year cycle, through VIS epidemics framework. →

Extensive analytical process with 3 Board decisions aligned with Gavi 6.0 development




8 pathogens in VIS 2024 longlist based on WHO landscape analysis

Scope and inclusion criteria

- ✓ Vaccines and immunisation products of relevance to Gavi-eligible countries
 - ✓ Licensed but not currently in Gavi's portfolio
 - ✓ With expected licensure by 2030

Two evaluation frameworks

- ✓ Endemics framework
- ✓ Epidemics framework 
- ✓ Which is used is informed by public health goal of investment




VIS 2024 longlist


Licensed

- Mpox 
- COVID-19

Licensed & pipeline


- Dengue (Est. 2023)
- Hepatitis E (Est. 2028) 

Pipeline

- Chikungunya (Est. 2025) 
- Group B streptococcus (Est. 2028)
- Tuberculosis (Est. 2029)
- Shigella (Est. 2029)

NB: vaccines for Marburg & other WHO R&D blueprint priority pathogens to be evaluated in real-time outside 5-year cycle if R&D advances

Consideration of new vaccine delivery platforms



Recommendation

The Gavi Alliance Programme and Policy Committee **recommends** to the Gavi Alliance Board that it:

- a) **Approve** the longlist of pathogens (hepatitis E, m-pox, dengue, COVID-19, tuberculosis, group B streptococcus, chikungunya, and shigella) with licensed or pipeline products, to assess as new potential investments in vaccines and immunisation products through the VIS process;
- b) **Approve** the evaluation criteria for potential new investments in vaccines and other immunisation products primarily intended for ***endemic disease prevention***; these include key ranking criteria (health impact, value for money, equity and social protection, Gavi's comparative advantage and economic impact) and modulating criteria that inform the ranking (global health security impact, other impact, broader health system benefits, implementation feasibility, alternative interventions, and contribution to global agenda);
- c) **Note** the evaluation approach for potential new investments in vaccines and other immunisation products primarily intended for ***epidemic disease prevention***; centred around four key questions: i) disease burden and risk, ii) vaccine impact and feasibility, iii) fit for Gavi and partners, and iv) financial implications; and
- d) **Request** as part of the VIS, the Secretariat undertake further analyses to evaluate the potential value of providing support to develop, strengthen and deliver vaccines at new touchpoints for specific target populations building upon lessons learned from other Gavi programmes.

Thank you